Ethylbromazolam

Benzodiazepine research chemical From Wikipedia, the free encyclopedia

Ethylbromazolam is a benzodiazepine derivative[1] which has been sold as a designer drug.[2][3][4] It is structurally similar to bromazolam, only differing by the substitution of the methyl group for an ethyl group on the triazole ring. It has been found in combination with its synthetic precursor desalkylgidazepam[5] in samples expected to contain alprazolam alone.

CAS Number
FormulaC18H15BrN4
Quick facts Identifiers, CAS Number ...
Ethylbromazolam
Identifiers
  • 8-bromo-1-ethyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H15BrN4
Molar mass367.250 g·mol−1
3D model (JSmol)
  • BrC1=CC=C(C2=C1)N3C(CN=C2C4=CC=CC=C4)=NN=C3CC
  • InChI=InChI=1S/C18H15BrN4/c1-2-16-21-22-17-11-20-18(12-6-4-3-5-7-12)14-10-13(19)8-9-15(14)23(16)17/h3-10H,2,11H2,1H3
  • Key:DKTGBMWWLATMHK-UHFFFAOYSA-N
Close

History

Ethylbromazolam has an extremely limited history of human usage. Very little is known about its pharmacological properties, metabolism, and potential toxicity.

It was first detected in the United Kingdom in February 2025,[6] and has subsequently been detected in New Zealand in March 2025[2] and at CanTEST in April 2025.[3]

References

Related Articles

Wikiwand AI